Investors evaluating the biotechnology sector are increasingly comparing companies by how effectively they are converting clinical momentum into market positioning. ARCT (Arcturus Therapeutics) and MRNA (Moderna) both operate in the messenger RNA (mRNA) space, yet they sit at opposite ends of the scale, maturity, and momentum spectrum. One is a small-cap developer of rare-disease and liver therapies, while the other is a large-cap platform company now pushing beyond vaccines into oncology. This stock comparison is most relevant to traders tracking relative performance and momentum, as well as longer-horizon investors weighing clinical catalysts against valuation risk.
Arcturus Therapeutics is a San Diego-based mRNA medicines company focused on liver and respiratory rare-disease therapeutics, built around its STARR self-amplifying mRNA technology and LUNAR lipid-mediated delivery system. Its lead clinical programs include ARCT-810 for ornithine transcarbamylase (OTC) deficiency and ARCT-032 for cystic fibrosis. In recent weeks, the stock gained attention after the company reported interim Phase 2 data for ARCT-810 showing the therapy was generally safe and well-tolerated while normalizing key biomarkers, alongside the introduction of a next-generation LUNAR 2.0 delivery platform. These updates prompted several analysts to lift ratings and price targets. Still, ARCT remains a high-beta, low-revenue company with a market capitalization of roughly $300 million and declining top-line results, leaving its share price highly sensitive to individual clinical readouts.
Moderna is a large-cap biotechnology company that pioneered mRNA-based vaccines and is now diversifying into respiratory vaccines and individualized cancer therapies. The dominant driver of recent sentiment has been intismeran autogene, its personalized cancer vaccine developed with Merck, which reported positive Phase 3 results in high-risk melanoma showing a 42% reduction in the risk of recurrence or death. That catalyst, combined with FDA (Food and Drug Administration) approval of its seasonal flu vaccine, a new chief operating officer appointment, and inclusion in the Nasdaq-100 index, propelled the stock to one of the strongest year-to-date performances in the S&P 500. The shares have since pulled back from their peak as investors digested detailed trial data and profit-taking, with the stock trading at a large multiple of revenue and above the consensus of many analyst price targets despite continued net losses.
Tickeron operates hundreds of AI-powered trading bots that collectively trade thousands of different tickers, each with its own strategy, timeframe, risk profile, and performance statistics. Because no single approach suits every market regime, Tickeron curates only the best-performing and most relevant systems into its Trending AI Robots section. These bots span a wide range of styles, from short-term momentum and swing strategies to longer-horizon trend-following models, and they monitor distinct sets of tickers, including biotech names like those covered here. For traders and investors who want to complement their own research with data-driven, rules-based signals, exploring this curated list can offer a useful view of which strategies are currently adapting well to shifting market conditions. Visit Trending AI Robots to review the available systems.
The two companies differ sharply across nearly every comparative dimension. In terms of business model, ARCT is a concentrated, early-stage rare-disease developer whose value hinges on binary clinical outcomes, while MRNA is a diversified platform with multiple approved products and a broad pipeline. Growth drivers also diverge: Arcturus relies on advancing its liver and respiratory candidates toward regulatory milestones, whereas Moderna is pivoting from a shrinking COVID franchise toward oncology, flu, and RSV (respiratory syncytial virus) opportunities. On momentum, Moderna's relative performance has been exceptional but recently volatile, while Arcturus has shown bursts of strength around data events without sustained trend consistency. Risk profiles contrast as well, with Arcturus carrying high beta and financing dependence, and Moderna facing valuation stretch after its rally. Sector exposure is broadly similar, but the scale of catalysts, liquidity, and institutional participation clearly favors Moderna.
Based on observable factors such as trend consistency, relative positioning, catalyst depth, and market liquidity, Tickeron's AI would currently favor MRNA over ARCT. Moderna's sustained upward momentum, larger institutional footprint, and multiple near-term catalysts give it a more consistent technical and fundamental profile, even though its valuation now sits above many analyst targets. Arcturus, by contrast, offers meaningful upside optionality but exhibits higher volatility and a narrower margin for execution error. The verdict is probabilistic rather than definitive, reflecting that relative performance can shift quickly as new data and market conditions emerge.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ARCT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In 46 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In 73 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ARCT entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for ARCT's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 229 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.712) is normal, around the industry mean (3.596). P/E Ratio (-3.108) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (443.347).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The 10-day RSI Oscillator for MRNA moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 26 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In 74 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
MRNA moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 217 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 108 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.010) is normal, around the industry mean (3.596). P/E Ratio (-31.853) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARCT | MRNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 61 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 32 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 64 | 34 | |
P/E GROWTH RATING 1..100 | 96 | 99 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRNA's Valuation (10) in the Biotechnology industry is in the same range as ARCT (32) in the Pharmaceuticals Major industry. This means that MRNA’s stock grew similarly to ARCT’s over the last 12 months.
MRNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that MRNA’s stock grew similarly to ARCT’s over the last 12 months.
MRNA's SMR Rating (97) in the Biotechnology industry is in the same range as ARCT (98) in the Pharmaceuticals Major industry. This means that MRNA’s stock grew similarly to ARCT’s over the last 12 months.
MRNA's Price Growth Rating (34) in the Biotechnology industry is in the same range as ARCT (64) in the Pharmaceuticals Major industry. This means that MRNA’s stock grew similarly to ARCT’s over the last 12 months.
ARCT's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as MRNA (99) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MRNA’s over the last 12 months.
| ARCT | MRNA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 86% | 1 day ago 84% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 85% |
| Advances ODDS (%) | 18 days ago 82% | 13 days ago 78% |
| Declines ODDS (%) | 1 day ago 88% | 4 days ago 87% |
| BollingerBands ODDS (%) | 5 days ago 81% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 83% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARCT’s FA Score shows that 1 FA rating(s) are green while MRNA’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARCT’s TA Score shows that 4 TA indicator(s) are bullish while MRNA’s TA Score has 3 bullish TA indicator(s).
ARCT (@Biotechnology) experienced а -10.89% price change this week, while MRNA (@Biotechnology) price change was -12.70% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.
MRNA is expected to report earnings on Feb 25, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To ARCT | 1D Price Change % | ||
|---|---|---|---|---|
| ARCT | 100% | -1.97% | ||
| CRSP - ARCT | 54% Loosely correlated | +0.44% | ||
| BCYC - ARCT | 52% Loosely correlated | -4.92% | ||
| NVAX - ARCT | 51% Loosely correlated | -3.24% | ||
| EDIT - ARCT | 51% Loosely correlated | -4.09% | ||
| PRME - ARCT | 50% Loosely correlated | -7.55% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MINN | 21.47 | 0.07 | +0.33% |
| Mairs & Power Minnesota Municipal Bond ETF (MINN) | |||
| VALQ | 67.98 | -0.89 | -1.29% |
| American Century U.S. Quality Value ETF (VALQ) | |||
| IQLT | 46.80 | -1.10 | -2.30% |
| iShares MSCI Intl Quality Factor ETF (IQLT) | |||
| FXR | 82.84 | -2.05 | -2.41% |
| First Trust Industrials/Producer Durables AlphaDEX Fund (FXR) | |||
| TTDU | 11.14 | -2.11 | -15.92% |
| T-REX 2X Long TTD Daily Target ETF (TTDU) | |||